Sequence information
Variant position: 38 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: 503 The length of the canonical sequence.
Location on the sequence:
VTQGDPVKPSRGPLVTCTCE
S PHCKGPTCRGAWCTVVLVRE
The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation: The multiple alignment of the region surrounding the variant against various orthologous sequences.
Human VTQGDPVKPSRGPLVTCTCES PHCKGPTCRGAWCTVVLVRE
Mouse LTRGDLAKPSK--LVNCTCES PHCKRPFCQGSWCTVVLVRE
Rat LTKGDLVKPSRGQLVNCTCEN PHCKRPICQGAWCTVVLVRE
Sequence annotation in neighborhood: The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:Type: the type of sequence feature. Positions: endpoints of the sequence feature. Description: contains additional information about the feature.
Type Positions Description
Chain
22 – 503
Serine/threonine-protein kinase receptor R3
Topological domain
22 – 118
Extracellular
Disulfide bond
34 – 51
Disulfide bond
36 – 41
Literature citations
Update on molecular diagnosis of hereditary hemorrhagic telangiectasia.
Richards-Yutz J.; Grant K.; Chao E.C.; Walther S.E.; Ganguly A.;
Hum. Genet. 128:61-77(2010)
Cited for: VARIANTS CYS-38; PRO-138; LYS-277; PRO-342; THR-400 AND GLU-486; VARIANTS HHT2 SER-96; GLY-217; GLU-226; ARG-280; ARG-294; GLN-328; HIS-335; ASP-347; SER-378; ARG-424; SER-449 AND PRO-479;
Disclaimer:
Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.